

# Biographies of International Advisory Group members

---

## Sophia Tickell, Chair of International Advisory Group and SustainAbility International



Sophia Tickell is the Chair of the MeTA International Advisory Group. She is also the Chairperson of SustainAbility, the award-winning, independent think tank and strategy consultancy, and Director of the Pharma Futures II project [www.pharmafutures.org](http://www.pharmafutures.org)

An historian, Sophia has worked on international development issues, both as a practitioner while living in Bolivia 1988–1992 and as Oxfam GB’s Senior Policy Advisor on the private sector, 1996-2003. In this role Sophia focused on the pharmaceuticals, oil and coffee industries. She has also worked as a journalist and as a trainer in advocacy techniques in Colombia, Zambia, Nepal and Senegal.

Sophia is a Member of Morley Fund Management’s SRI Advisory Committee and the European Healthcare Innovation Leadership Network.

## Mavis Owusu-Gyamfi, Deputy Director, Private Sector Development, UK Department for International Development (DFID)



Mavis Owusu-Gyamfi is currently responsible for setting DFID’s policy direction on private sector development (PSD) and managing a team of technical specialists that provide advice to key partners in developing countries, the international community and the UK government. Prior to this she led the team responsible for managing the Department’s portfolio to support economic growth in Nigeria. She has extensive experience in private sector led growth and has provided technical advice to governments in East, West and Southern Africa as well as the Eastern Caribbean. This included facilitating the first PSD Strategies in Ghana and Tanzania and successfully managing economic development portfolios exceeding \$400m in a number of countries.

She is a political economist by training and an MPhil graduate of the Institute of Development Studies at the University of Sussex. Her publications include *Binding Constraints to Growth in Nigeria* (Palgrave Macmillan, 2008) and *Growth and Competitiveness* (World Bank, 2007).

## Frédérique Santerre, Director of IFPMA Health Care Systems Committee



Frédérique Santerre joined the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) during the fall 2005, and is Director of the IFPMA Health Care Systems Committee.

Her major responsibilities at the IFPMA deal with health care systems issues and innovation policies, encompassing pricing and reimbursement, health care reform and financing, ethical business and code of marketing, good corporate governance and corporate social responsibility, Health Technology Assessment (HTA) and health economics. She manages the IFPMA Code of Pharmaceutical Marketing Practices, supporting its implementation and fostering transparency and ethical promotion of medicines worldwide via the IFPMA Code Compliance Network (CCN), and processing complaints and breaches of the Code. She acts as the industry observer to the WHO International Working Group for Drug Statistics Methodology (ATC/DDD classification system). She is in charge of the recently launched IFPMA President's Health Care Quality Scorecards Initiative that addresses health indicators and health quality issues. Finally, she is responsible for the newly created IFPMA Global HTA Industry Network focusing on improving access to medicines and promoting the value of innovation.

Prior to her arrival at the IFPMA, she held various positions; in academia, Harvard University Kennedy School of Government, Cambridge, MA and Graduate Institute of International Studies, Geneva; in international organisations, the International Union for Conservation of Nature (IUCN), the Ramsar Convention on Wetlands, the UN High Commissioner on Refugees (UNHCR), the International Telecommunications Union (ITU) and the World Health Organisation; in non-governmental organisations, the International Centre for Trade and Sustainable Development (ICTSD) and *Médecins du Monde*. In addition, she worked for the World Economic Forum (Davos).

As a post-doctoral Research Fellow at Harvard University's Kennedy School of Government in the Science, Technology and Society Program in Cambridge, MA, she ran two parallel research projects on biotechnology regulation. She acted as a consultant with the World Health Organisation's Tropical Disease Department, on the public-private partnership for the Treatment and Drug Resistance Network (TDRN) for Sleeping Sickness.

She completed her PhD in International Relations, *summa cum laude*, at the Graduate Institute of International Studies (Geneva). Her doctoral dissertation, *Encounter in Bio-Complexity: Global Governance of Biodiversity, Biotechnology and Intellectual Property Rights*, addressed the contested issues of negotiation and governance of new technologies around three key international agreements: WTO TRIPs Agreement, the Convention on Biological Diversity and the Cartagena Protocol on Biosafety. Frédérique Santerre holds a Master's degree in International Relations (Master, Graduate Institute of International Studies, Geneva), a Master's degree in International and Comparative Politics (MPhil, University of Glasgow) and a graduate degree in Economics (Sorbonne University, Paris).

## **Dr Eva M A Ombaka, Coordinator of the Ecumenical Pharmaceutical Network (EPN)**



Dr Eva M A Ombaka trained as a pharmacist at University of Aston in Birmingham, UK where she also did her PhD research in Pharmaceutical Microbiology. Her 30-year career in pharmacy has spanned hospital practice, academia, and manufacturing. In the last fifteen years she has been involved in pharmaceutical policy development, capacity building for better pharmacy practice and in advocacy. Her main advocacy areas are in the field of access to medicines. She has also being involved in several courses to promote the rational use of medicines and on drugs and therapeutic committees. She was the winner of Olle Hansson award for 2007 for her work in rational use of medicines. She is currently the coordinator of the Ecumenical Pharmaceutical Network (EPN) that brings church-related health services around the world to address pharmaceutical issues together. She is an honorary pharmaceutical adviser to the World Council of Churches. She is also involved in the work of Sustainable Healthcare Enterprises Foundation (SHEF) that is pioneering the franchising of community-based pharmaceutical services to enable access to essential medicines and other basic health services. Dr Ombaka is Tanzanian and is currently working and living in Nairobi, Kenya.

## **Dr Kenneth Hartigan-Go, Executive Director of the Zuellig Family Foundation**



Dr Kenneth Y Hartigan-Go has served as Executive Director of the Zuellig Family Foundation. A practicing internist and medical toxicologist, he earned his Bachelor of Science and Doctor of Medicine degrees from the University of the Philippines, underwent his internal medicine and medical toxicology training at the Philippine General Hospital, and obtained a postgraduate doctoral degree from the University of Newcastle-upon-Tyne, United Kingdom in 1998.

From 1999-mid-2001, he was the Deputy Director of the Bureau of Food and Drugs, and programme manager of the Philippine national drug policy programme, a position he utilised as a platform to advance advocacies for better drug quality, rational drug use, sound drug regulation, and lower drug prices, advocacies which he continues to work for today through his roles as consultant and adviser for the Department of Health, the World Health Organization, academe, multilateral agencies, and the private sector.

Kenneth is on the faculty of the newly-opened Ateneo School of Medicine and Public Health, and was on the core team that shaped its innovative curriculum combining medicine with MBA degree. Previous to this he was professor of pharmacology and toxicology of the University of the Philippines College of Medicine. He is the president of the Corporate Network for Disaster Response from 2003 to present and sits in the Board of Regents of the Philippine College of Physicians. He is a tireless proponent of progressive public health policy, health sector reform, and disaster preparedness.

## **Robin Hodess, Director of Policy and Research Transparency International**



Dr Robin Hodess, Transparency International's Director of Policy and Research since December 2003, joined Transparency International in June 2000 to manage the Global Corruption Report. She came to Berlin from New York, where, since 1998 she had been a programme officer for the Carnegie Council on Ethics and International Affairs, responsible for the Council's programme on economic globalisation, "Justice and the World Economy".

Prior to this, she taught media and politics at the Free University of Berlin and at Leipzig University (1997-98) and served as assistant director for international security programs at the Center for War, Peace and the News Media at New York University (1992-94). Dr Hodess holds a PhD and MPhil in international relations from Cambridge University (UK) and a BA in history from the University of Pennsylvania (USA).

## **David Jamieson, Deputy Director for Country Programs and Partnerships with the PEPFAR-funded Supply Chain Management Project (SCMS)**



David is a health sector specialist with a special interest in the HIV and AIDS crisis and assisting countries to meet the Millennium Development Goals. Based in Washington DC, he has overall responsibility for SCMS client, donor and partner relations. SCMS is the major procurement and supply project of ARVs, other essential drugs, rapid test kits and a wide range of laboratory equipment and supplies to PEPFAR and other HIV and AIDS implementing partners. Before joining SCMS in January 2006 David worked for Crown Agents based in the UK for 20 years, specialising in developing country supply chains. He has worked on projects funded by all of the major donors such as the Global Fund for Aids, TB and Malaria, World Bank, DFID, USAID, UNFPA, WHO and UNAIDS.

## **John McHale, MSc, BComm, Managing Director of Research for Fidelity Management & Research (UK Inc.)**



John manages a team of ten analysts in London who cover global equities. Prior to becoming Managing Director of Research at Fidelity, in 2008, he headed a global team of healthcare analysts at Pioneer Investments and was an analyst for large cap US & European Pharmaceuticals, based in their Dublin, Ireland office.

John's career in finance began in 1989 as a Corporate Finance Executive with Bank of Ireland. In 1991 he moved to Irish Life Investment Managers where over the course of nine years he worked in equity portfolio management and analysis for both domestic and international markets. During his career he has analysed healthcare, media, personal care, paper & packaging, construction and financial industries. He managed several segregated pension funds at Irish Life and became a Senior Manager in 1997. John has a First Class Honours Degree in Banking & Finance, and an MSc in Investments & Treasury from Dublin City University, where he also lectured part-time for four years.

## **Richard Laing, Team leader for the Medicine Information and Evidence for Policy, Essential Medicines and Pharmaceutical Policies Department, WHO**



Richard Laing is a physician who worked, for 18 years, at all levels in the Ministry of Health Zimbabwe. After receiving postgraduate degrees in public health and health policy he spent 13 years in Boston USA. He initially worked for an international consulting company establishing the International Network for the Rational Use of Drugs.

He was then a Professor of International Public Health at Boston University School of Public Health before joining WHO in mid 2003 as a medical officer. He has served on a number of WHO Expert Committees. He has an extensive list of academic publications and is one of the editors and authors of the standard text *Managing Drug Supply*. At WHO, he is responsible for editing the *Essential Drugs Monitor* and for coordinating training and research related to promoting rational use of drugs in the community. He was one of the authors of the *Priority Medicines for Europe and the World* report. Most recently he has been engaged in working on measurement of medicines pricing and availability as part of the joint WHO/HAI project on medicine prices. Recently, Richard has been appointed as team leader for the Medicine Information and Evidence for Policy in the essential Medicines and Pharmaceutical Policies Department.

## **Richard Calland, Executive Director of Open Democracy Advice Centre and Head of the Institute for Democracy in South Africa (Idasa) “Right to Know” Programme**



Richard Calland is Associate Professor in the Public Law Department at the University of Cape Town and Director of its Democratic Governance and Rights Unit. He teaches constitutional and human rights law, and some administrative law. He specializes in the law and practice of the right to access to information and whistle blowing protection; in administrative justice; in public ethics; and in constitutional design – largely derived from his work as programme manager of the Political Information & Monitoring Service at Idasa ([www.idasa.org.za](http://www.idasa.org.za)) – the leading democracy think tank in Africa – which he led from its inception in 1995 until 2003. In 2000, he founded the Open Democracy Advice Centre (ODAC), a law centre based in Cape Town, which promotes the “right to know”, advising whistleblowers, advocating law reform and taking test case litigation on access to information. He continues to play a role at Idasa as Acting Manager of the Economic Governance Programme that was initiated in January 2007, and serves as part-time Executive Director of ODAC.

Dr Calland was a member of the Transparency Task team of the Institute for Public Dialogue at Columbia University, which is led by Professor Joseph Stiglitz. Professor Calland has in recent years served as an expert consultant to the Carter Center, the foundation led by former US President Jimmy Carter, advising on various transparency projects in Bolivia, Jamaica, Nicaragua, Peru and Mali. In South Africa, Professor Calland writes a fortnightly political column for the *Mail and Guardian* newspaper, “Contretemps”, and is a regular commentator in the media. In 2005, he spent two terms at Cambridge University, as a visiting scholar at the Lauterpacht Centre on International Law. In 2006, he spent a month as a visiting lecturer in constitutional law at the law department of Meiji University, Tokyo.

Before coming to South Africa in 1994, Calland practiced law at the London Bar (called in 1987 at Lincoln's Inn). He holds an LLM from the University of Cape Town, a Diploma in World Politics from the London School of Economics and a BA (Hons) Law from the University of Durham. He is a Senior Associate of the Cambridge Programme for Industry at the University of Cambridge, acting as a member of faculty at seminars with business leaders working on issues of sustainable development and climate change.

### **Tim Reed, Director, Health Action International (Global)**



Before entering academia in 1994, Tim had a successful career as director of a UK based foundation caring for adults with physical, learning and behavioural difficulties. He then achieved a first class honours degree in Sociology and Development studies at the University of Sussex, before being awarded a PhD in 2003 for his work on pharmaceutical regulation in Central and Eastern Europe.

Leaving a lectureship in political sociology behind, he joined Health Action International in 2006 as Director and has since then spent most of his time consolidating the HAI global network and restructuring the foundation to improve its global platform as a leading NGO in medicines regulation throughout the world.

### **Dilip Shah, Secretary General, Indian Pharmaceutical Alliance**



Dilip Shah has 42 years of varied experience in the pharmaceutical industry and currently holds the following positions:

- Member of the Management Committee of the International Generic Pharmaceutical Alliance (IGPA)
- Secretary-General of the Indian Pharmaceutical Alliance (IPA), an Association of 15 large research based national companies. Together they service about one-third of the domestic market, account for one-third of exports and contribute 90 per cent of R & D spending in the pharmaceutical industry
- Member, The World Bank Generics Consultative Group
- Co-chairman of the FICCI's Committee on Pharmaceutical
- Member of the Board of Advisors of Pharmabiz.com (Weekly)
- Member of the Advisory Panel for the Business Briefing: PharmaGenerics UK
- Editor, Asia and India, Journal of Generic Medicines, UK
- CEO, Vision Consulting Group, a firm specialised in strategic planning

Author of the first book on "Drug Pricing in India" and occasional contributor to business press, he graduated from the premier business school in India, Indian Institute of Management (IIM), Ahmedabad, and has been a guest faculty member for their Management Development Programmes. Before starting the Vision Consulting Group in 1997, he was a Member of the Board of Directors of Pfizer-India for whom he worked for 30 years. He has represented Indian pharmaceutical industry at several international meetings and conferences, including WTO workshops on the TRIPS agreement.

## **David Ofori-Adjei, Professor of Tropical Clinical Pharmacology, University of Ghana Medical School**



Dr David Ofori-Adjei is Professor of Tropical Clinical Pharmacology; and Medicine and Therapeutics at the Centre for Tropical Clinical Pharmacology, University of Ghana Medical School. He is a former Director of Noguchi Memorial Institute for Medical Research at the University of Ghana, Legon. His interests include the promotion of the rational use of drugs both at the national and international level, pharmacotherapy of tropical diseases especially malaria, schistosomiasis and Buruli ulcer; pharmacogenetics and clinical trials.

He has played a major role in the selection of essential medicines, the preparation of therapeutic guidelines as well as malaria control in Ghana.

He has worked on WHO expert panels and working groups related to medicines (selection of essential medicines, drug use statistics methodology and adverse drug events reporting). Presently, he is the Chair of the Coordinating Committee of the National Malaria Control Programme, the team leader of a group assisting the National Health Insurance Authority to improve medicines use, Editor-in-Chief of the Ghana Medical Journal, the Country Coordinator of the International Network for the Rational Use of Drugs (INRUD) in Ghana and member of the Advisory Council of the Clinical Division of IUPHAR.

He is also the Co-chair of the Ghanaian-Dutch Collaboration on Health Research and Development, represents the West African Health Organisation (WAHO) on the Developing Country Coordinating Committee of the European and Developing Countries Clinical Trial Partnership and chairs the Clinical Trials Review Committee of the Ghana Food & Drugs Board.

## **Dr Taher Abu El-Samen, Chair of Steering Committee, Jordan MeTA Project**



Taher Abu El-Samen is a Medical Doctor, and specialist in hospitals and health facilities administration from Jordan University. He also has a degree in Health Planning from Leeds University. Currently he is the Secretary General of the High Health Council in Jordan. He is involved directly in the national health policy process, and in collaborating efforts among all health sectors in Jordan, with main focus on national health priority issues: Health Insurance Reform to attain comprehensive coverage, Medical Liability, Joint Procurement of Drugs, Continuing

Medical Education CME, and establishing the Emergency and First Aid Commission.

He is the team leader of National Health Accounts (NHA), which is considered as an important instrument for drawing up the national health policy.

Prior to this he worked in Health Sector Reform issues with the MOH through collaboration with the World Bank and USAID health projects. He has extensive experience in improving national health systems. He has also worked with WHO, undertaking several health consultancies.

## **Armin Fidler, Lead Adviser for Health Policy and Strategy in the Human Development Network of the World Bank**



An Austrian national, Dr Armin Fidler joined the World Bank in 1993 and started to work in the Latin America and Caribbean (LAC) Region. In 2000 he became the Manager for Health, Nutrition, Population for the Europe and Central Asia Region. He was responsible for the Bank's health strategy, lending and technical assistance programs, including all analytical and advisory work in the European Union and the countries of the former Soviet Union. In 2008 Dr Fidler was appointed Lead Adviser for Health Policy and Strategy in the Human Development Network of the World Bank at the global level.

Dr Fidler holds a Doctor of Medicine Degree (MD) from the University of Innsbruck, Austria, and Master of Public Health (MPH) and Master of Science (MSc) degrees in Health Policy and Management, both from Harvard University's School of Public Health. He also holds certificates in Management from the Harvard Business School and in Public Finance and Welfare Economics from the London School of Economics and Political Science.

Dr Fidler has an Adjunct Faculty appointment at the George Washington University School of Public Health in Washington DC, and at the Management Center Innsbruck (MCI), a private Austrian University.

Prior to joining the World Bank, Dr Fidler served as Sub-Regional Advisor for the World Health Organization, based in Mexico and Central America after serving in the Epidemic Intelligence Service (EIS) at the US Centers for Disease Control and Prevention (CDC) in Atlanta, GA.

He serves on the Board of Directors at the German School in Washington DC.

## **Madike Seye, Vice President Sub-Saharan, GlaxoSmithKline**



Mr Seye has been in his current post since 2006, and with the firm that is now GlaxoSmithKline since 1990. His former posts include General Manager, West & Central Africa; Commercial Director, West & Central Africa; Sales Director, West & Central Africa -- all with GlaxoSmithKline - - and Marketing Director, West & Central Africa; Sales Director, Francophone West Africa; and Sales Manager Senegal, Mali -- with SmithKline Beecham. His first job for SmithKline & French was as a sales representative in Senegal, having formerly been a research assistant at the Institut Pasteur Dakar Senegal for two years.

Mr Seye has a BSc from Dakar University. He is Non-executive Director GSK Consumer Nigeria PLC and belongs to the Manufacturer's trade association (Nigeria, Senegal, Ivory Coast); the Groupement des exportateurs industrie pharmaceutique (GEIP France); the Côte d'Ivoire chamber of commerce; and the Ivorian and Belgium chamber of commerce.

## **A J M (Ton) Hoek, Secretary General and Chief Executive Officer of the International Pharmaceutical Federation (FIP)**



A J M (Ton) Hoek was born in The Hague, in 1955 and studied pharmacy at the State University of Leiden in the Netherlands. He obtained his Master of Science degree in 1983 and graduated as a Pharmacist in 1984. He had training periods in both pharmaceutical practice and the hospital pharmacy.

During his student years he was active in the pharmaceutical student organisation Aesculapius and served as president during 1980/1981. After university Ton Hoek joined the pharmaceutical industry and worked at several management positions both in R&D as well as in marketing.

From 1999, Ton Hoek has been the General Secretary and Chief Executive Officer of FIP, the International Pharmaceutical Federation. The FIP is the global federation of national organisations of pharmacists and pharmaceutical scientists dedicated to improving the access to and value of appropriate medicine use worldwide, and contributing to changes in science, practice and health policies worldwide. The FIP is a non-governmental organisation in partnership with the World Health Organization in Geneva. As of 1999 Ton Hoek also serves as Executive Director of the FIP Foundation for Education and Research.

## **Goodwell Lungu, Executive Director of Transparency International Zambia**



Goodwell Lungu has been working in the Anti-Corruption field for the past 12 years. He holds two University Degrees in Sociology and Development Studies obtained from the University of Zambia in 1995. He also holds a Master of Philosophy Degree in Criminology obtained from the University of Cambridge in the United Kingdom where he specialised in public sector corruption prevention. He is a fellow of the Cambridge Commonwealth Society and also holds a Postgraduate Diploma in Project Management from Cambridge University.

He has held and continues to hold key positions such as having been the Head of the Community Education Department at the Anti-Corruption Commission in Zambia where he worked for eight years from 1996 to 2004. He was also a country coordinator for a World Bank Youth for Good Governance Project in 2003. He has also held the position of an Advisory Member for the Drug Enforcement Commission's Anti-Money Laundering Unit in 2004 to 2005. He is also an anti-corruption expert adviser for U4 helpdesk.

He has attended several and made key presentations at both local and international anticorruption fora/conferences/workshops and was a key adviser to the 12th International Anti-Corruption Conference (IACC) in Guatemala 2006. He also attended the first UNCAC states parties conference in Jordan in 2006.

He has written several articles and done research on anti-corruption and good governance and has appeared on many Radio and Television Programmes on public and private stations in Zambia on a regular basis appearing fortnightly. He is currently Executive Director for Transparency International Zambia and Board Chairperson for MS Zambia which is the Danish Association for International Cooperation.

## **Elías Melitón Arce Rodrigues, Vice Minister of Health of the Government of Peru**



Dr Arce's recent positions include Vice president of the National Academy of Medicine (2006-2007), Member of the Directorate of CEDRO (2005-2007), Member of the Doctrine and Legislation Committees of the Peruvian College of Physicians since 2003, and President of the Ethics Committee for Research and Development of Technologies of the Children's Health Institute since 2002. He has also represented Peru at a number of international health summits in the last 35 years.

Dr Arce gained a Bachelor degree in Medicine from the National University of San Marcos in Lima, Peru in 1959 and a Doctorate in Medicine in 1971. He has is a distinguished Professor at the National University of San Marcos since 1994 and has taught the Master's and Doctorate programmes in Public Health and a Doctorate in Medicine since 2000.

## **Paul A Lartey, CEO LaGray Chemical Company**



Dr Paul Lartey is the President and CEO of LaGray Chemical Company, a pharmaceutical manufacturing firm in Ghana. He spent over 20 years in drug discovery and development in the US pharmaceutical industry, working for Abbott Laboratories, Upjohn, Pharmacia and Pfizer. He was Director of Infectious Diseases Drug Discovery Research at Pfizer. Driven with a passion to bring his expertise home in the quest to improve access to medicines, he co-founded LaGray Chemical Company, the first in West Africa with technology for the manufacture of active pharmaceutical ingredients

as well as finished dosage forms.

He holds a Bachelor degree in Pharmacy and a Masters in Pharmaceutical Chemistry from the University of Science and Technology, Ghana. He obtained his PhD in Medicinal Chemistry at the State University of New York at Buffalo and post-doctoral training in Synthetic Organic Chemistry at Yale University. His interest and expertise are in antibacterial, antifungal and antiviral drug design, discovery and development. He has several publications and patents in drug discovery.

## **Rustam Kurmanov, Director General of the Department of Drug Provision and Medical Equipment under Ministry of Health, Kyrgyzstan**



As a head of the Department of Drug Provision and Medical Equipment (DDPME) Dr Kurmanov is responsible for the implementation of principal points of the National Drug Policy, including drug safety, quality, effectiveness and availability. Before the appointment on this position (2005) he had been working in this regulatory authority as from the formation in 1997 beginning his career in Marketing Authorization. Simultaneously he engages in scientific work. Dr Kurmanov has written in 52 scientific publications and has authored two monographs. He is a Doctor of Medicine, Professor, Academician of the International Human

Safety and Ecology Academy (Sankt-Petersburg, Russian Federation).

## Seru Morries, Principal Pharmacist at the Ministry of Health in Uganda



Seru Morries is Pharmacist by background, trained at Pyatigorsk Institute of Pharmacy in the former Soviet Union. He did as well a Master in Public Health specialising in Health Economics at the University of Cape Town in South Africa.

He works currently as the Principal Pharmacist at the Ministry of Health (MOH) Headquarters in Uganda and is a member of the MeTA National Secretariat. Most of his work involves but is only not limited to training and supervising Health workers on medicine logistics management and rational medicine use.

Prior to joining MOH head quarters, he worked as a Hospital Pharmacist for 14 years.

